Gulley James L, Madan Ravi A
Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Asian J Urol. 2016 Oct;3(4):278-285. doi: 10.1016/j.ajur.2016.08.008. Epub 2016 Aug 30.
The clinical development of immunotherapy has gained significant impetus in recent years across the field of medical oncology. Mounting preclinical and clinical data have demonstrated the potential of immune-based treatments to augment anti-tumor immune responses. With one of the first modern immunotherapies approved in prostate cancer and multiple others in late stage development, immune treatment strategies need to be optimized to ensure the best clinical outcomes. Combination strategies with androgen deprivation therapy, anti-androgen therapy, radiation and chemotherapy have demonstrated the potential maximize immune response in prostate cancer patients. These combinations are currently being evaluated in clinical trials at every stage of prostate cancer from the newly diagnosed to the most advanced stages. Data from these studies will provide guidance for the future clinical implementation of immunotherapy in prostate cancer.
近年来，免疫疗法的临床开发在整个医学肿瘤学领域获得了显著的推动力。越来越多的临床前和临床数据表明，基于免疫的治疗方法具有增强抗肿瘤免疫反应的潜力。随着前列腺癌中首批现代免疫疗法之一获批，以及其他多种疗法处于后期开发阶段，免疫治疗策略需要优化，以确保获得最佳临床结果。与雄激素剥夺疗法、抗雄激素疗法、放疗和化疗的联合策略已显示出在前列腺癌患者中最大化免疫反应的潜力。目前，这些联合疗法正在从新诊断到最晚期的前列腺癌各个阶段的临床试验中进行评估。这些研究的数据将为未来免疫疗法在前列腺癌中的临床应用提供指导。
